Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Ondine accelerates pivotal antimicrobial trial after $11m financing

LinkedIn

Ondine’s Phase III trial will investigate its Steriwave system for nasal photodisinfection before surgery.

Ondine Biomedical will initiate a Phase III trial of its light-activated antimicrobial technology to reduce healthcare-associated infections (HAIs) early after a $11m fundraising boost.

The Canadian biotech said it experienced strong support from existing investors in the latest funding round and added several significant new investors, including M&G Investment Management. Ondine shared that it is also in talks with what it describes as a major US healthcare group about a further potential investment of up to $4m.

Ondine CEO Carolyn Cross said: “The capital raised enables us to advance our goal to have the first patient treated in December 2024.

“The robust interest we have had in this fundraise is testament to the excitement around our groundbreaking light-activated antimicrobial technology, particularly in the context of the growing death toll caused by antimicrobial resistance (AMR).”

The technology is already marketed outside of the US as Steriwave. It acts using a process dubbed photodisinfection, using light-activated disinfectant to destroy viruses, bacteria, and fungi without causing the development of resistant strains of microbes.

According to the company, Steriwave has resulted in significant reductions in surgical site infection rates, patient readmission numbers, length of stay, and antibiotic usage. The technology received a CE mark in Europe in 2020 and is used within the UK National Health Service (NHS) trusts.

Ondine’s trial, which plans to enrol 5,000 patients and is designed as a group-randomised crossover study, will be conducted across 14 of its US partner HCA Healthcare’s hospital sites and compare standard of care (SoC) infection prevention practices with and without nasal photodisinfection.

The trial aims to conclude enrolment by mid-2025, with an early data readout anticipated in late-2025.

Elsewhere in the antimicrobial devices field, US-based nanoscience company EVŌQ Nano’s antimicrobial medical device platform demonstrated effectiveness against the world’s leading pathogens implicated in HAIs earlier this year.